Features Associated with Therapy Switch Among PPD CorEvitas Psoriasis Registry Patients
Identification and recognition of these features and combinations thereof can facilitate shared decision-making between clinicians and patients to improve both outcomes of and patient satisfaction with biologic therapy.
Authors
- Melissa Eliot (ORCID: https://orcid.org/0000-0003-3280-935X)
- Natasha Trujillo
- Heather J. Litman (ORCID: https://orcid.org/0000-0003-3511-4078)
- Sandra I. Main
- Andrea M. Austin
- Robert Low
- Omeed Nabavian
- Scott C. Henderson
Institutions
- Thermo Fisher Scientific (United States) (US)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1007/s13555-025-01646-1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- National Psoriasis Foundation
- Eli Lilly and Company
- Pfizer
- Ortho Dermatologics
- LEO Pharma
- Genentech
- Chugai Pharmaceutical
- Janssen Pharmaceuticals